SUN PHARMA EYES 7-FOLD RISE IN US PRODUCT LAUNCH

Sun Pharmaceutical Industries Ltd. forecast a seven-fold jump in U.S. product launches next year and detailed the spin-off of its research and development unit.
Shareholders in the company, which spends a relatively high 12 per cent of sales on R&D, will receive equal shares in its R&D unit and remaining generic drug business, Sun Pharma Managing Director Dilip Shanghvi said at the Reuters India Summit on Monday.
Sify